Search Within

Shanu Modi

  1. "Springer"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (7)
Groups
  1. Breast Medicine Service (18)
  2. Department of Medicine (18)
  3. Solid Tumor Oncology Division (18)
  4. Survivorship Research (11)
  5. GSK Faculty (6)
  6. Department of Pathology and Laboratory Medicine (4)

More Groups

People
  1. Clifford Hudis (7)
  2. David Solit (3)
  3. Diana Lake (3)
  4. Mario Lacouture (3)
  5. Andrew Seidman (2)
  6. Jacqueline Bromberg (2)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (1)
  4. 2020 (1)
  5. 2017 (1)
  6. 2015 (1)

More Years

Publications
  1. Breast Cancer Research and Treatment (14)
  2. Annals of Surgical Oncology (1)
  3. Current Breast Cancer Reports (1)
  4. Current Oncology Reports (1)
  5. Virchows Archiv (1)
Publishers
  1. Springer (18)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
    Meeting Abstract

    Krop, I. E.; Beeram, M.; Modi, S.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S. N.; Lutzker, S. G.; Burris, H. A.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results
    Meeting Abstract

    Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Burris, H. A.; Krop, I. E.; Modi, S.; Rodon, J.; Lutzker, S. G.; Holden, S. N.; Bhattacharya, S.; Sliwkowski, M.; Beeram, M.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Incidence of amenorrhea (A) in breast cancer (BC) patients (pts) <= 40 years of age after paclitaxel (T)-based adjuvant chemotherapy (CT)
    Meeting Abstract

    Fornier, M. N.; Modi, S.; Hudis, C. A.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer
    Meeting Abstract

    Albain, K.; Elledge, R.; Gradishar, W. J.; Hayes, D. F.; Rowinsky, E.; Hudis, C.; Pusztai, L.; Tripathy, D.; Modi, S.; Rubi, S.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • An update on epidermal growth factor receptor inhibitors
    Journal Article

    Modi, S.; Seidman, A. D.
    Current Oncology Reports (2002)

    Fulltext@MSK | Save